Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6

Core Viewpoint - Jupiter Neurosciences, Inc. is hosting a webinar to discuss its scientific platform, clinical development plans, and commercial strategy for 2026, focusing on its lead asset JOTROL™ and its dual-path approach in both pharmaceutical and consumer markets [2][4]. Group 1: Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company targeting neuroinflammation and healthy aging through a dual-path strategy [4]. - The company is advancing a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [4]. - JOTROL™, a proprietary enhanced resveratrol formulation, has shown significantly improved bioavailability compared to earlier resveratrol products [4][5]. Group 2: JOTROL™ and Clinical Development - JOTROL™ achieves over nine times higher bioavailability compared to previous resveratrol formulations, which is critical for its effectiveness [6]. - The company is advancing JOTROL™ toward a Phase IIa clinical trial in Parkinson's Disease, with a broader focus on CNS disorders including Alzheimer's Disease and Friedreich's Ataxia [4][6]. - The Phase I study results of JOTROL™ were published in reputable journals, indicating a strong foundation for upcoming trials [6]. Group 3: Nugevia Product Line - Nugevia™ is a premium longevity and performance supplement line that utilizes the same patented JOTROL™ technology, targeting cognitive health, skin vitality, and cellular energy [8][9]. - Nugevia products are developed under pharmaceutical standards and are based on peer-reviewed clinical data, differentiating them from conventional supplements [9]. - The product line aims to support healthy aging through formulations that enhance cognitive resilience, mitochondrial energy, and skin vitality [8].